Earli exists to make cancer a benign experience. Earli does that by turning cancer against itself: genetically forcing it to reveal itself early, thereby distinguishing it from benign lesions, and then to kill itself. Based on technology originally from Stanford's renowned Gambhir lab, Earli designs programmable genetic constructs that "flip on" like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope that acts as a "docking station" for imaging agents, or a therapeutic protein for immune system activation against the tumor. Thus, Earli's platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence.
Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers.
Earli has raised $92m in three rounds from investors including Andreessen Horowitz, Khosla Ventures, Emerson Collective, Stanford, Perceptive Advisors, Casdin Capital, Marc Benioff, Sands Capital, Breyer Capital, Tailwinds (American-Korean) etc.
Its Scientific Advisory Board includes Jim Allison (Nobel Laureate, Immuno Oncology), Bob Langer (MIT, co-founder Moderna), Phil Greenberg (Hutch, co-founder Juno), Pam Sharma (MD Anderson), Charlie Rudin (Sloan Kettering), Alan Ashworth (UCSF Cancer Center).
Who You Are
- You share our same sense of dedication, scientific passion and entrepreneurial spirit
- You work well in a fast-paced and extremely focused startup environment
- You are not only smart, but clever and constantly think outside the box
- You are able to make logical decisions in an instant when there is little time to evaluate
- You are a natural communicator and relationship builder
- You stay calm under high pressure and stress
- You have the ability to multi-task in a serious way, with an extreme attention to detail
- You become a representative of the core DNA of the company through who you are
The Position
Earli is currently seeking a highly motivated and detail-oriented Research Associate to join the Therapeutics team.
Your Primary Responsibilities
- Extract DNA, RNA, proteins and cells from tumors and mouse tissues to quantify target expression using FACS, ELISA, RT-qPCR and other techniques.
- Culture cancer cell lines, human PBMCs and mouse primary cells to evaluate immune cell activation, cancer cell killing and other readings related to drug activity
- Analyze data and maintain accurate records of experimental procedures, data, and results in electronic lab notebooks and databases.
- Present and discuss results in group meetings
Your Required Experience, Knowledge and Skill
- BS or MS degree in Cell Biology, Molecular Biology, or related sciences field with hands on wet lab experience.
- ELISA, RT-qPCR and gel electrophoresis experience is strongly preferred.
- Experience in mammalian cell culture is needed
- Experience on cell-based assays strongly preferred
- Effective communication and interpersonal skills, with the ability to work collaboratively in a team setting.
- Ability to think independently, multi-task effectively, and fully integrate into a high achieving team environment.
The base salary for this role is $60k-$95k per year.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
Top Skills
What We Do
Earli mission is to make cancer a benign experience.
Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner.
Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
